Perioperative immune checkpoint inhibitors with or without chemotherapy versus placebo with or without chemotherapy in elderly people with localised non-small cell lung cancer.

Date publication

juillet 2026

Journal

The Cochrane database of systematic reviews

Auteurs

Membres identifiés du Cancéropôle Est :
Pr WESTEEL Virginie

Tous les auteurs :
Plissonneau E, Marchal C, Malouf R, Calais F, Westeel V, Orillard E

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/42440312

Résumé

Lung cancer is typically a cancer of the elderly, with a median age at diagnosis of 71, and more than one third of the people diagnosed with lung cancer are over 75 years old. Immune checkpoint inhibitors (ICIs) have revolutionised the treatment of cancers, including lung cancer. ICIs targeting the programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) axis, administered in the neoadjuvant setting, the adjuvant setting, or both, are currently the standard of care for resectable non-small-cell lung cancer (NSCLC) worldwide. These ICIs are commonly used in combination with platinum-based chemotherapy and have shown superior efficacy in patients eligible for curative surgery. The concept of immunosenescence, which refers to age-related changes in the immune system - particularly a decline in the efficiency of T-cell mediated responses - raises concerns about the benefits of ICIs in the elderly population.

Mots clés

Humans, Carcinoma, Non-Small-Cell Lung, drug therapy, Lung Neoplasms, drug therapy, Randomized Controlled Trials as Topic, Immune Checkpoint Inhibitors, therapeutic use, Aged, Antineoplastic Combined Chemotherapy Protocols, therapeutic use, Chemotherapy, Adjuvant, Bias, Placebos, therapeutic use, Quality of Life

Référence

Cochrane Database Syst Rev. 2026 07 13;7(7):CD016104